Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine | NEJM
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine - ScienceDirect
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients | NEJM
Boosting immunity to COVID-19 vaccines | Nature Medicine
For Transplant Recipients, Third Time May Be the Charm for Better COVID Vaccine Protection
Third Dose of COVID-19 Vaccine Increases Neutralizing Antibodies Against Omicron in Cancer Patients - Cancer Therapy Advisor
Testing fractional doses of COVID-19 vaccines | PNAS
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Low circulation of antibodies correlates with risk for COVID-19 among patients on dialysis
Covid Vaccine Booster Gives Effective Antibody Protection Against Omicron: Study
Vaccines | Free Full-Text | Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients | NEJM
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals - The Lancet
Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom | Nature Microbiology
SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis - ScienceDirect
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 | Nature Medicine
Data shows greater, broader SARS-CoV-2 neutralizing antibodies with third dose of Pfizer/BioNTech vaccine
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects | Microbiology Spectrum
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 - The Lancet
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT - The Lancet Haematology
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors | Nature Medicine
CDC Library: COVID-19 Science Update: 07/30/2021
Comirnaty, INN-COVID-19 mRNA Vaccine (nucleoside-modified)
Largest Study to Date Demonstrates Most Blood Cancer Patients Benefit From a Third Primary Dose of mRNA COVID-19 Vaccine | Leukemia and Lymphoma Society
